Xbrane Biopharma AB (XBRANE) Stock Statistics & Valuation Metrics

Xbrane Biopharma AB has a market cap or net worth of kr211.16M. The enterprise value is kr13.13M.

Xbrane Biopharma AB has 20,605,349 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xbrane Biopharma AB’s return on equity (ROE) is -1.28 and return on invested capital (ROIC) is -54.45%.

The current PE Ratio of Xbrane Biopharma AB is 1.1. Xbrane Biopharma AB’s PEG ratio is 0.00899.

In the last 12 months, Xbrane Biopharma AB had revenue of 198.70M and earned -266.22M in profits. Earnings per share was -27.50.

In the last 12 months, operating cash flow was -89.22M and capital expenditures -90.25M, giving a free cash flow of -179.47M billion.

Xbrane Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Xbrane Biopharma AB upcoming earnings date is May 5, 2026, TBA (Confirmed).

Xbrane Biopharma AB as a current ratio of 1.13, with Debt / Equity ratio of 0.00%

In the past 12 months, Xbrane Biopharma AB has paid 11.59M in taxes.

Xbrane Biopharma AB EV to EBITDA ratio is -1.46, with an EV/FCF ratio of -1.43.

Xbrane Biopharma AB has kr93.56M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr93.56M billion.

Gross margin is 69.94%, with operating margin of -109.67%, and net profit margin of -133.98%.

The average price target for Xbrane Biopharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―